Closed Loop Medicine completes recruitment into clinical study that is required for regulatory submission of its insomnia product CLM-IN01


Closed Loop Medicine Ltd, a healthcare company focused on developing drug + digital combination products, the next generation of pharmaceutical products announces that it has completed recruitment for its critical clinical trial in the development of its combination product CLM-IN01 for insomnia.

The company successfully completed dosing of all required participants with its proprietary drug, despite the trial being conducted in the midst of a COVID-19 lockdown. 

The global sleep economy is expected to grow to $585 billion by 2024, yet very few solutions for insomnia are helping people sleep better. Insomnia is a condition that afflicts 10-15% of the adult population and is often a further complication in certain neurodegenerative conditions, cancer, anxiety, depression and women’s health. 

The combination products being developed by Closed Loop Medicine transform a patient’s care by integrating drug therapy and digitally delivered care solutions. 

Published on: 24.03.21

Article sourced from